Netscientific shares picked up 2% after another encouraging update from portfolio company and cancer treatment developer PDS Biotech.
PDS hosted a Key Opinion Leader event on May 8, 2024, during which experts in head and neck squamous cell cancer discussed positive, updated VERSATILE-002 data and the unmet need in HPV16-positive HNSCC.
First quarter results from PDS showed a loss of US$10.6 million and cash at the period end of US$66.6 million.
Shares in Netscientific rose by 12.5p to 65.5p
-- adds share price movement--